Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

Maria R. Baer(University of Maryland, Baltimore), Richard A. Larson(Wayne State University)

Blood

August 15, 2002

10.1182/blood.v100.4.1224.h81602001224_1224_1232

Cited by 365

Related Papers

Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator

|Clinical Cancer Research|2005|238

Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

|PLoS ONE|2013|74

PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition–Dependent GSK-3β–Mediated c-Myc and Pim-1 Proteasomal Degradation

|Molecular Cancer Therapeutics|2021|25

Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress

|Oncotarget|2016|22

Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation

|Cancer Research Communications|2024|12